ARTBIO Secures $132 Million in Series B Round to Boost Cancer Therapy Development
Deal News | Jul 29, 2025 | PR Newswire Cision ARTBIO
ARTBIO, a clinical-stage radiopharmaceutical company focused on alpha radioligand therapies (ARTs), has announced a successful closing of a $132 million Series B financing round. The round was co-led by new investors Sofinnova Investments and B Capital, with participation from seasoned investors F-Prime, Omega Funds, and Third Rock Ventures. Additional new investors include the Qatar Investment Authority and Alexandria Venture Investments. The proceeds will be used to advance the company’s lead asset, AB001, into Phase II clinical trials for metastatic castration-resistant prostate cancer. Furthermore, the funding will support ARTBIO’s supply chain expansion through proprietary AlphaDirect™ technology, which allows flexible production of clinical-grade lead-212 and daily doses. ARTBIO aims to redefine cancer care by optimizing alpha-precursor isotopes and tumor-specific targets, aspiring to create therapeutics with higher efficacy and safety standards.
Sectors
- Biotechnology
- Healthcare
- Pharmaceuticals
Geography
- United States – The headquarters of ARTBIO is in Cambridge, Mass., making the United States a primary geography for the company and its operations.
- Norway – ARTBIO has roots and scientific legacies linking back to Oslo, Norway, including historic work at Norway's Radium Hospital.
- Qatar – Qatar Investment Authority's participation in the financing round indicates relevance to Qatar as an important geography.
Industry
- Biotechnology – The article is about ARTBIO, a radiopharmaceutical company, which falls under the biotechnology industry because it is involved in developing therapies using biological systems.
- Healthcare – As ARTBIO develops cancer treatment therapies, this aligns with the healthcare industry's focus on medical advancements and patient care.
- Pharmaceuticals – ARTBIO is involved in producing pharmaceuticals in the form of alpha radioligand therapies to treat cancer, putting it within the pharmaceutical industry.
Financials
- $132 million – The amount raised in the Series B financing round by ARTBIO.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ARTBIO | Target | Company | A clinical-stage radiopharmaceutical company developing alpha radioligand therapies. |
| Sofinnova Investments | Investor | Company | A venture capital firm leading the Series B financing in ARTBIO. |
| B Capital | Investor | Company | A venture capital firm co-leading the investment in ARTBIO. |
| F-Prime Capital | Investor | Company | An existing investor providing continued support in the financing round. |
| Omega Funds | Investor | Company | An existing investor participating in the Series B financing round. |
| Third Rock Ventures | Investor | Company | An existing investor contributing to ARTBIO's financing. |
| Qatar Investment Authority | Investor | Company | A new investor joining the Series B round. |
| Alexandria Venture Investments | Investor | Company | A new investor participating in the Series B. |